Skip to content

rTMS-induced Cumulative Pattern of sBDNF in Chronic Schizophrenia

Short-Term Response of Serum Brain-Derived Neurotrophic Factor to Repetitive Transcranial Magnetic Stimulation in Patients With Chronic Schizophrenia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01427088
Enrollment
21
Registered
2011-09-01
Start date
2011-08-31
Completion date
2011-11-30
Last updated
2015-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

rTMS-induced cumulative pattern of sBDNF

Brief summary

This study aims at investigating the neuroplastic potential and the possible factors affecting rehabilitation in chronic schizophrenia patients on stable medication, by investigating the cumulative pattern of serum BDNF representing the neuroplasticity in the brain, through quantitative stimulus such as rTMS.

Detailed description

Subjects who have been enrolled for this study will take baseline evaluation for sociodemographic data and serum level of BDNF, plasma Prolaction, and magnesium, etc. And then, weekday regular stimulation through rTMS will be applied on DLPFC of brain. After the completion of stimulation for 2 weeks, the change or response of serum BDNF will be analyzed and compared.

Interventions

DEVICECR Technology, TAMAS for repetitive TMS

repetitive TMS, lef DLPFC, 20Hz, 100% of MEP, 2weeks

Sponsors

Jeonbuk Provincial Maeumsarang Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
25 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* duration of illness over 10 years * on stable medication, antipsychotics * no change on medication within at least 2 weeks * Diagnosis of Schizophrenia according to DSM-IV-TR

Exclusion criteria

* left or both-handedness * anticonvulsant use * lorazepam equivalent over 3 mg

Design outcomes

Primary

MeasureTime frame
change from baseline of serum BDNF concentrationbaseline-1 week-2 week-4 week

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026